scorecard

You Searched For "Mylan" and got 20 results


Sort By:


Business Insider Latest Story Image
1 min read

USFDA accepts proposed biosimilar application by Mylan, Biocon for review

The application seeks approval of Bevacizumab for the first-line and second-line treatment of pati…

PTI   


Business Insider Latest Story Image
1 min read

Mylan, Biocon launch biosimilar of cancer drug Herceptin in US

New Delhi, Dec 2 () Biotechnology major Biocon and drug firm Mylan NV on Monday announced the launc…

PTI   


Business Insider Latest Story Image
2 mins read

USFDA pulls up Mylan for manufacturing violations at Andhra plant

New Delhi, Nov 18 () American health regulator USFDA has pulled up Mylan Laboratories for violation…

PTI   


Business Insider Latest Story Image
1 min read

Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licence

New Delhi, Nov 27 () Biotechnology major Biocon on Wednesday said that US health regulator has appr…

PTI   


Business Insider Latest Story Image
1 min read

Biocon, Mylan win patent litigation against Sanofi in US for insulin glargine device

"In October 2017, Sanofi had initiated patent infringement litigation against our NDA in the US Di…

PTI   


Business Insider Latest Story Image
3 mins read

Mylan is tumbling on reported shortages of its life-saving EpiPens

According to the report, recent actions by US regulators indicate the supply drought could continue…

Daniel Strauss   


Business Insider Latest Story Image
1 min read

Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall

New Delhi, Jan 9 () Amid the voluntary recall of Nizatidine API by Mylan, Solara Active Pharma Scie…

PTI   


Emma Court   


Business Insider Latest Story Image
2 mins read

FDA approves Teva's generic EpiPen in blow to Mylan

"Today's approval of the first generic version of the most-widely prescribed epinephrine auto-injec…

Charlotte Hu,Reuters   


Business Insider Latest Story Image
2 mins read

Mylan skyrockets after securing a merger with Pfizer's off-patent drug unit

The new company will be rebranded and renamed, and Heather Bresch - the chief executive officer of …

Daniel Strauss   


Business Insider Latest Story Image
2 mins read

Mylan is recalling EpiPens in the US

Mylan was called out in August 2016 for raising the price of the EpiPen to $608.61 from $93.88 over…

Lydia Ramsey   


Business Insider Latest Story Image
3 mins read

Investigations are piling up at Mylan

But that's not the only legal matter Mylan's facing. The company's also under investigation generic…

Lydia Ramsey   


Business Insider Latest Story Image
1 min read

Wall Street analysts are throwing shade at Pfizer's deal with Mylan, saying it will hurt profits through 2020

Several Wall Street analysts noted that the company's decision to merge Upjohn - Pfizer's off-paten…

Ben Winck   


Charlotte Hu   


Business Insider Latest Story Image
2 mins read

Mylan, Dr Reddy's, Aurobindo, and Torrent Pharma can't sell generic Gilenya that is patented by Novartis

A US court has ordered generic drug makers including Mylan, Dr Reddy's Laboratories, Aurobindo Ph…

Business Insider Latest Story Image
4 mins read

Not everyone is buying into Mylan's EpiPen price plan

"This step seems like a PR fix more than a real remedy, masking an exorbitant and callous price hik…

Lydia Ramsey   


Business Insider Latest Story Image
1 min read

EpiPen-maker Mylan misses on Q3 earnings

Excluding items, such as the $465 million Department of Justice settlement expense, Mylan said it h…

Lydia Ramsey,Reuters   


Business Insider Latest Story Image
3 mins read

The FDA just approved a generic EpiPen, and analysts think it has the potential to upend Mylan's hold on the market

In May 2017, the FDA said that there was a shortage of EpiPens in the US, because of issues with th…

Lydia Ramsey   


Business Insider Latest Story Image
1 min read

Aurobindo and Intas submit binding offers to buyout Teva UK

Teva is selling its assets after it acquired Allergan Plc's generics business for $40.5-billion in …